<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gene G Hunder, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H359018453"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Immunoglobulin A (IgA) vasculitis (IgAV; formerly Henoch-Schönlein purpura [HSP]) is the most common systemic vasculitis among children. Ninety percent of cases occur in the pediatric age group. In contrast to other forms of childhood systemic vasculitis, IgAV is usually self-limited, at least in children, and is characterized by a tetrad of clinical manifestations that vary in their presence and order of presentation:</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura (leukocytoclastic vasculitis) in patients with neither thrombocytopenia nor coagulopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Arthralgia and/or arthritis</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney disease</p><p></p><p>IgAV occurs more often in children than in adults, but kidney involvement is more likely to occur and be more severe in older children and adults, prompting consideration of more aggressive therapy. The kidney manifestations of IgAV, including treatment and prognosis, will be reviewed here. Other aspects of IgAV are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6407.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Management"</a>.)</p><p></p><p class="headingAnchor" id="H1024066230"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Kidney involvement has been reported in approximately 20 to 54 percent of children with IgAV [<a href="#rid1">1-7</a>] and may be more prevalent among older children and adults [<a href="#rid8">8</a>].</p><p>In an analysis of 161 patients (112 children, 49 adults) with IgAV nephritis from the multicenter Cure Glomerulonephropathy (CureGN) study, the median age at diagnosis was 9 years in children and 35 years in adults [<a href="#rid9">9</a>]. Male sex was predominant among both children and adults with IgAV nephritis (63 and 59 percent, respectively).</p><p>Risk factors predicting kidney involvement are not well established, but several clinical and laboratory features have been reported as potential risk factors. In one meta-analysis, older age at onset, gastrointestinal symptoms, persistent purpura, relapse, elevated white blood cell (WBC) count, elevated platelet count, elevated antistreptolysin O (ASLO) titer, and low C3 were associated with kidney involvement in children with IgAV [<a href="#rid10">10</a>]. Other factors associated with the development of kidney disease include delay in diagnosis, angioedema, and central nervous system (CNS) involvement [<a href="#rid11">11,12</a>].</p><p>Several reports of IgAV nephritis following coronavirus disease 2019 (COVID-19) or COVID-19 vaccination have been described [<a href="#rid13">13-16</a>]. However, the exact relationship and causality are unclear in most cases.</p><p class="headingAnchor" id="H3731949294"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>IgAV is characterized by the tissue deposition of IgA-containing immune complexes [<a href="#rid17">17</a>]. The histologic findings in the kidney are identical to those in IgA nephropathy, suggesting that the two disorders may have a similar pathogenesis. Likewise, the finding of high circulating levels of galactose-deficient IgA1 (Gd-IgA1) in patients with both IgA nephropathy and IgAV suggests a common underlying pathogenetic mechanism [<a href="#rid18">18</a>]. The observation of the simultaneous occurrence of IgAV and IgA nephropathy in each of two twins after an adenovirus infection is further evidence in support of a common pathogenesis [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/3095.html" rel="external">"IgA nephropathy: Pathogenesis"</a>.)</p><p>IgA deposition is prominent in both IgAV and IgA nephropathy  (<a class="graphic graphic_picture graphicRef69895" href="/z/d/graphic/69895.html" rel="external">picture 1</a>), but the kidney injury may be mediated at least in part by immunoglobulin G (IgG) autoantibodies directed against mesangial cell antigens [<a href="#rid20">20,21</a>]. It has also been proposed that IgA1 antibodies generated against endothelial cells could activate neutrophils via the IgA Fc receptor FcalphaRI (CD89), inducing neutrophil migration and activation and ultimately causing tissue damage in IgAV [<a href="#rid22">22</a>]. The course of the kidney disease and circulating antibody titers are roughly parallel, and these autoantibodies do not appear to be present in patients with IgAV who do not have kidney involvement [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3037300437"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The classic tetrad of IgAV is rash, arthralgias, abdominal pain, and kidney disease, which can develop in any order and at any time over a period of several days to several weeks [<a href="#rid2">2,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H1200204866"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Kidney involvement (IgAV nephritis) typically occurs within a few days to one month after the onset of systemic symptoms [<a href="#rid6">6</a>]. The most common presentation is microscopic or macroscopic glomerular (dysmorphic) hematuria with or without red blood cell (RBC) casts and mild or moderate proteinuria [<a href="#rid4">4,6,9</a>]. Nephrotic-range proteinuria, an elevated serum creatinine, and/or hypertension are present in a minority of patients; these findings are associated with a worse kidney prognosis [<a href="#rid6">6</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p>IgAV nephritis is generally mild in children (particularly young children), while adults are more likely to develop moderate to severe disease, as manifested by a higher frequency of nephrotic syndrome, hypertension, and an elevated serum creatinine [<a href="#rid23">23-27</a>]. In the Cure Glomerulonephropathy (CureGN) cohort of 161 patients with IgAV nephritis, the median estimated glomerular filtration rate (eGFR) at the time of kidney biopsy was 109 mL/min/1.73 m<sup>2</sup> among children compared with 67 mL/min/1.73 m<sup>2</sup> among adults; only 4 percent of children, compared with 20 percent of adults, had an eGFR &lt;30 mL/min/1.73<sup>2</sup> [<a href="#rid9">9</a>]. Long-term kidney impairment can occur in 20 to 44 percent of patients who initially present with nephritic or nephrotic syndrome [<a href="#rid6">6,28-30</a>].</p><p>There is a general correlation between the severity of the kidney manifestations and the findings on kidney biopsy [<a href="#rid28">28,31-35</a>]. Patients with only asymptomatic hematuria, for example, usually have only focal mesangial proliferation, whereas patients with proteinuria have more marked cellular proliferation and, if nephrotic or nephritic, may have crescent formation [<a href="#rid35">35,36</a>]. Patients with repeated attacks of purpura or macroscopic hematuria often have exacerbation of kidney manifestations and biopsy-confirmed worsening of glomerular lesions. (See <a class="local">'Pathologic findings'</a> below.)</p><p class="headingAnchor" id="H909036590"><span class="h2">Pathologic findings</span><span class="headingEndMark"> — </span>On kidney biopsy, light microscopy can show a wide spectrum of glomerular changes, ranging from isolated mesangial proliferation  (<a class="graphic graphic_picture graphicRef62380" href="/z/d/graphic/62380.html" rel="external">picture 2</a>) to focal and segmental proliferation to severe crescentic glomerulonephritis. The diagnostic finding is dominant or codominant IgA deposition, mostly IgA1, in the mesangium on immunofluorescence, similar to that seen in IgA nephropathy  (<a class="graphic graphic_picture graphicRef69895" href="/z/d/graphic/69895.html" rel="external">picture 1</a>). In addition, immunofluorescence frequently reveals IgG, immunoglobulin M (IgM), fibrinogen, and C3 in the glomeruli. Immunofluorescence staining for C1q is rarely found in IgAV nephritis and should suggest the possibility of lupus nephritis. By electron microscopy, electron-dense deposits are typically found in the mesangial areas, occasionally extending out into the peripheral capillary loops  (<a class="graphic graphic_picture graphicRef58102" href="/z/d/graphic/58102.html" rel="external">picture 3</a>).</p><p class="headingAnchor" id="H4266163738"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H855688655"><span class="h2">Monitoring for kidney disease</span><span class="headingEndMark"> — </span>Patients with IgAV who do not present with kidney involvement should be monitored for the development of IgAV nephritis:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with an initially normal urinalysis should have follow-up urine dipstick testing at least once a week for one month and then once every two weeks for five months since 97 percent of children with IgAV who develop kidney disease do so within this time period [<a href="#rid6">6</a>]. Children with isolated hematuria with nonnephrotic-range proteinuria that persists after six months should have periodic monitoring of the serum creatinine every three to six months as long as the hematuria and proteinuria persist. Children with isolated hematuria without proteinuria do not need periodic monitoring of the serum creatinine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults who present with features of IgAV but without kidney involvement should be monitored with a urinalysis to screen for proteinuria and/or hematuria, serum creatinine, and blood pressure check at three-month intervals for at least one year.</p><p></p><p>Metabolomic profiling has identified putative biomarkers that may predict the development of kidney disease among patients with IgAV who do not present with kidney involvement [<a href="#rid37">37</a>]; however, additional studies validating these findings in larger populations are needed.</p><p class="headingAnchor" id="H2668119477"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of IgAV nephritis is typically based upon the clinical presentation. In most cases in children, the development of hematuria, proteinuria, and/or elevated serum creatinine in association with palpable purpura, abdominal pain, and arthritis/arthralgia is so characteristic that no further investigation is usually needed to confirm the diagnosis. If further confirmation is required, a skin biopsy can be performed. Biopsy of the skin lesions reveals inflammation of the small blood vessels (leukocytoclastic vasculitis), which is most prominent in the postcapillary venules, and IgA deposition by immunofluorescence microscopy  (<a class="graphic graphic_diagnosticimage graphicRef52548 graphicRef66296" href="/z/d/graphic/52548.html" rel="external">image 1A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p>A kidney biopsy can also be performed to establish the diagnosis, but this invasive procedure is generally reserved for patients in whom the diagnosis is uncertain or who have more severe kidney involvement. In general, we perform a kidney biopsy in all patients with suspected or confirmed IgAV nephritis who present with proteinuria &gt;1 g/day and/or impaired kidney function to assess the severity of the histologic lesions (particularly the degree of crescent formation), which may guide treatment decisions as well as inform prognosis. This approach is largely consistent with the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [<a href="#rid38">38</a>]. Based upon data in patients with IgA nephropathy [<a href="#rid39">39,40</a>], some adult nephrologists choose to biopsy patients with lower levels of proteinuria (eg, &gt;500 mg/day or &gt;750 mg/day). (See <a class="local">'Pathologic findings'</a> above and <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H1584639615"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The classic tetrad (palpable purpura without thrombocytopenia or coagulopathy, arthritis/arthralgia, abdominal pain, and kidney disease) is virtually pathognomonic of IgAV in children. The differential diagnosis includes antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, clotting disorders (such as the antiphospholipid syndrome), and sepsis [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Clinical manifestations in children'</a> and  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>.)</p><p>IgAV in adults must be distinguished from other systemic autoimmune diseases (such as hypersensitivity vasculitis, cryoglobulinemia, ANCA-associated vasculitis, and systemic lupus erythematosus) and infection-related glomerulonephritis, which can produce similar symptoms but are treated differently. A period of follow-up may be necessary to distinguish among these conditions. One report of 178 patients with IgAV or hypersensitivity vasculitis found that hypersensitivity vasculitis was present with 74 percent accuracy in patients who had <strong>no more than two</strong> of the following criteria [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura</p><p class="bulletIndent1"><span class="glyph">●</span>Bowel angina</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria</p><p class="bulletIndent1"><span class="glyph">●</span>Age at onset ≤20 years</p><p></p><p>The combination of kidney disease and hemoptysis can simulate the presentation of ANCA-associated vasculitis (microscopic polyangiitis or granulomatosis with polyangiitis) or anti-glomerular basement membrane (GBM) disease. (See  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Glomerulonephritis (hematuria with proteinuria, kidney function impairment, or other manifestations)'</a>.)</p><p class="headingAnchor" id="H2184161165"><span class="h1">PREVENTION OF IGAV NEPHRITIS</span><span class="headingEndMark"> — </span>In patients with IgAV who do not have kidney involvement at the time of presentation, we do <strong>not</strong> recommend treatment with glucocorticoids to prevent the development of IgAV nephritis.</p><p>Early administration (at the time of presentation) of oral glucocorticoids has not been shown to be effective at preventing IgAV nephritis. In one trial, 352 children (age &lt;18 years) with new-onset IgAV were randomly assigned to <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (2 mg/kg/day [maximum dose of 80 mg] for seven days, followed by 1 mg/kg/day [maximum dose of 40 mg] for seven days) or placebo for 14 days [<a href="#rid43">43</a>]. At 12 months after disease onset, the prevalence of proteinuria (defined as a urine protein-to-creatinine ratio &gt;20 mg/mmol) was similar between the two groups; changes in kidney function were not assessed. Similarly, two smaller randomized trials that compared oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> with placebo among children presenting with IgAV found no difference in the risk of kidney involvement (defined by the presence of microscopic hematuria or proteinuria) within one year of disease onset [<a href="#rid44">44,45</a>]. There are no studies evaluating preventive strategies in adults with IgAV.</p><p class="headingAnchor" id="H2121181960"><span class="h1">MANAGEMENT OF IGAV NEPHRITIS</span><span class="headingEndMark"> — </span>Most patients with IgAV receive only supportive therapy with hydration, rest, and analgesics. Some evidence suggests that glucocorticoids enhance the rate of resolution of the arthritis and abdominal pain; however, they do not appear to prevent recurrent disease [<a href="#rid2">2</a>]. The general approach to therapy of IgAV is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6407.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Management"</a>.)</p><p>Treatment of IgAV nephritis depends upon whether the patient is a child or an adult and upon the severity of the kidney disease. Immunosuppressive therapy should be considered <strong>only</strong> in patients who present with marked proteinuria (&gt;1 g/day) and/or impaired kidney function during the acute episode. As previously stated, such patients should undergo a kidney biopsy since the severity of the histologic lesions (particularly the degree of crescent formation) appears to be the best indicator of prognosis. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p>By contrast, patients with limited evidence of kidney involvement (such as microscopic or macroscopic hematuria with mild proteinuria [&lt;1 g/day] and normal kidney function) are generally not subjected to kidney biopsy and are not given specific therapy but should be followed closely for worsening of proteinuria or impairment of kidney function. However, as previously mentioned, some adult nephrologists choose to biopsy patients with lower levels of proteinuria (eg, &gt;500 mg/day or &gt;750 mg/day) and use the biopsy results to guide treatment for those with evidence of kidney damage. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p class="headingAnchor" id="H1279461993"><span class="h2">Initial approach</span></p><p class="headingAnchor" id="H4198944173"><span class="h3">Children</span><span class="headingEndMark"> — </span>In children with IgAV nephritis, our approach to treatment depends upon the severity of kidney disease at the time of presentation:</p><p class="bulletIndent1"><span class="glyph">●</span>In children who present with limited evidence of kidney involvement (ie, microscopic or macroscopic hematuria, proteinuria &lt;1 g/day, and normal serum creatinine), we do not treat with immunosuppressive therapy for IgAV nephritis. We do not routinely initiate an ACE inhibitor or ARB, since such patients typically fully recover without these agents. We monitor urine protein excretion (by spot urine protein-to-creatinine ratio or 24-hour urine protein collection) once per week for one month, then every two weeks for two months to assess for disease progression. In patients who develop an increase in proteinuria to ≥1 g/day, we perform a kidney biopsy to evaluate the need for more aggressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children who present with more severe kidney involvement (ie, proteinuria ≥1 g/day, elevated serum creatinine, or evidence of crescentic glomerulonephritis [&gt;10 percent crescents] on kidney biopsy), we suggest immunosuppressive therapy with glucocorticoids. We administer three pulses of intravenous (IV) <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 1 g/1.73 m<sup>2</sup> (one dose daily, or on alternate days, for three doses), followed by oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 30 mg/m<sup>2</sup> (once daily for one month, then every other day for two months). We monitor urine protein excretion (by spot urine protein-to-creatinine ratio or 24-hour urine protein collection) and serum creatinine once per week for one month, then every two weeks for two months. Upon completion of three months of glucocorticoid therapy, subsequent treatment depends upon the degree of persistent proteinuria and kidney function impairment:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who respond to treatment with a reduction in proteinuria to &lt;0.5 g/day <strong>and</strong> stable or improved serum creatinine, we discontinue glucocorticoids. We continue to monitor urine protein excretion on a monthly basis without additional immunosuppressive treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with persistent proteinuria &gt;0.5 g/day <strong>or</strong> worsening serum creatinine, we obtain a repeat kidney biopsy to determine if there is ongoing inflammatory injury. We start all patients with persistent proteinuria &gt;0.5 g/day after three months on an ACE inhibitor or ARB [<a href="#rid38">38</a>]. If the kidney biopsy demonstrates evidence of persistent, active inflammation (ie, proliferative glomerulonephritis), we repeat a course of pulse IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> followed by oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, as detailed above. If the kidney biopsy reveals chronic lesions without active inflammation, we discontinue glucocorticoids and continue the ACE inhibitor or ARB indefinitely to reduce proteinuria, unless contraindicated.</p><p></p><p class="bulletIndent1">Children who do not respond to glucocorticoids may be candidates for other immunosuppressive therapies. These therapies, and the evidence supporting them, are discussed elsewhere in this topic. (See <a class="local">'Alternative therapies'</a> below.)</p><p></p><p>Our approach to therapy in children is largely consistent with the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines [<a href="#rid38">38</a>] and the European consensus-based recommendations for diagnosis and treatment of IgAV [<a href="#rid46">46</a>]. </p><p>There are no randomized, controlled trials to support the use of glucocorticoids in children with IgAV nephritis, and data come primarily from observational studies. High-dose IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (250 to 1000 mg/day for three days) followed by oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg/day for three months) may be beneficial in patients with severe disease (usually defined as crescentic nephritis) [<a href="#rid33">33,47,48</a>]. This regimen is primarily aimed at reversing the inflammatory process (such as macrophage infiltration), rather than the IgA deposition itself. One prospective, uncontrolled study used this regimen in 38 children presenting with the nephrotic syndrome and/or crescents affecting more than 50 percent of glomeruli [<a href="#rid33">33</a>]. Only four (10 percent) progressed to end-stage kidney disease (ESKD), three of whom had been treated late in the course of their disease. Thus, early therapy may be important in preventing irreversible glomerular injury.</p><p>Other regimens that have been evaluated in children with crescentic nephritis include glucocorticoids and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (19 of 21 children showed improvement in kidney function in an uncontrolled study) [<a href="#rid49">49</a>] and multidrug regimens such as glucocorticoids, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a>, or glucocorticoids, cyclophosphamide, heparin/<a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and dipyridamole [<a href="#rid50">50-53</a>]. However, since spontaneous recovery is often observed in patients with crescent formation, it remains unknown whether these regimens are superior to no or less aggressive therapy.</p><p class="headingAnchor" id="H2938693565"><span class="h3">Adults</span><span class="headingEndMark"> — </span>In adults with IgAV nephritis, our approach to therapy depends upon the severity of kidney disease at the time of presentation and the likelihood of progression to kidney failure. There are limited data to guide the optimal treatment of adults with IgAV nephritis, and our approach is primarily based upon clinical trials of patients treated for IgA nephropathy (see  <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">"IgA nephropathy: Treatment and prognosis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In adults who present with limited evidence of kidney involvement (ie, microscopic or macroscopic hematuria, proteinuria &lt;1 g/day, and normal serum creatinine), we do not treat with immunosuppressive therapy for IgAV nephritis. We treat all adults with proteinuria &gt;0.5 g/day with an ACE inhibitor or ARB to reduce proteinuria, unless contraindicated. We monitor urine protein excretion (by spot urine protein-to-creatinine ratio or 24-hour urine protein collection) and serum creatinine every two weeks for one month, then every two months for six months to assess for disease progression. In patients who develop an increase in proteinuria to ≥1 g/day or a sustained increase in serum creatinine greater than that expected from use of an ACE inhibitor or ARB, we perform a kidney biopsy to evaluate the need for more aggressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In adults who present with more severe kidney involvement (ie, proteinuria ≥1 g/day, elevated serum creatinine, or evidence of crescentic glomerulonephritis on kidney biopsy), we suggest immunosuppressive therapy with glucocorticoids. We typically administer a six-month course of glucocorticoids similar to that used for patients with IgA nephropathy. We give pulse IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (250 to 500 mg daily for three days), followed by oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.5 mg/kg orally once daily [maximum dose 40 mg/day]). In addition, we treat all such patients with an ACE inhibitor or ARB to reduce proteinuria, unless contraindicated. We monitor urine protein excretion (by spot urine protein-to-creatinine ratio or 24-hour urine protein collection) and serum creatinine every two weeks for one month and then monthly for the first six months:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who respond to treatment with a reduction in proteinuria to &lt;1 g/day <strong>and</strong> stable or improved serum creatinine, we gradually taper the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose. We start the taper at two months of treatment with the plan to decrease the dose by 10 mg every two weeks until the patient reaches a dose of 10 mg daily, at which time treatment can be slowly tapered further. This approach is similar to that used in the treatment of some patients with IgA nephropathy who receive glucocorticoid therapy. (See  <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">"IgA nephropathy: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have persistent proteinuria ≥1 g/day <strong>or</strong> worsening serum creatinine after four to six months of treatment, we obtain a repeat kidney biopsy to determine if there is ongoing inflammatory injury [<a href="#rid38">38</a>]. If the kidney biopsy reveals chronic lesions without active inflammation, we discontinue glucocorticoids and continue treatment with an ACE inhibitor or ARB indefinitely to reduce proteinuria, unless contraindicated. If the kidney biopsy demonstrates evidence of persistent, active inflammation (ie, proliferative glomerulonephritis), either <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> or <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is a reasonable choice for second-line therapy. The evidence for either therapy is based on very limited, low-quality data. Given the potential toxicities of each therapy, we prefer a six-month trial of mycophenolate mofetil (MMF) at 500 to 1000 mg twice daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In adults who have a large number of active crescents on kidney biopsy (over 20 to 25 percent), some clinicians would treat with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or MMF in addition to the six-month course of glucocorticoids. Some contributors to this topic prefer to give cyclophosphamide (500 mg IV every two weeks for a total of six doses), based upon its effectiveness in the treatment of other forms of rapidly progressive crescentic glomerulonephritis, while other contributors prefer to give rituximab. Evidence for these therapies is discussed elsewhere in this topic. (See <a class="local">'Alternative therapies'</a> below.)</p><p></p><p>Adults who cannot receive or who do not respond to glucocorticoids may be candidates for other immunosuppressive therapies. These therapies, and the evidence supporting them, are discussed elsewhere in this topic. (See <a class="local">'Alternative therapies'</a> below.)</p><p class="headingAnchor" id="H3992110879"><span class="h2">Alternative therapies</span><span class="headingEndMark"> — </span>Although not supported by controlled clinical trials, several alternative therapies have been used with variable efficacy in patients with IgAV nephritis. We reserve the use of these therapies for patients in whom initial therapy as discussed above has not been effective. These therapies, and the evidence supporting their use, are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a><strong> mofetil</strong> – One study compared the effects of MMF plus low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.4 to 0.5 mg/kg) with full-dose prednisone (0.8 to 1.0 mg/kg) in 53 patients, aged 14 to 62 years, with IgAV nephritis and heavy proteinuria (&gt;2 g/day) [<a href="#rid54">54</a>]. There was no significant difference in the rate of remission between the treatment groups at 6 and 28 months, suggesting that MMF may be useful for inducing and maintaining remission as a glucocorticoid-sparing agent. In another study of 18 children with IgAV nephritis and nephrotic-range proteinuria who had an inadequate response to glucocorticoids and were treated with MMF, 89 percent showed a significant decrease in proteinuria after one month of treatment [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> has been shown to be effective in the treatment of adults and children with glucocorticoid-resistant IgAV nephritis in a small number of observational studies and case series [<a href="#rid56">56-59</a>]. As an example, in one multicenter study of 22 adults with IgAV, 18 of whom had kidney involvement, patients received rituximab for refractory or relapsing disease or because of contraindications to conventional immunosuppressive therapy [<a href="#rid59">59</a>]. Rituximab was administered either as 375 mg/m<sup>2</sup> weekly for four consecutive weeks or as two 1000 mg doses given two weeks apart, alone or in combination with other immunosuppressive therapies. During a median of 24 months, 20 patients (91 percent) achieved remission; 7 of these 20 experienced subsequent relapse of disease. Proteinuria decreased significantly compared with baseline, and estimated glomerular filtration rate (eGFR) remained stable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong> – Limited observational data suggest that <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may be beneficial in patients with IgAV and severe proteinuria [<a href="#rid60">60,61</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one small trial of 24 children with IgAV and nephrotic-range proteinuria or crescentic glomerulonephritis, 15 were randomly assigned to either <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (5 mg/kg for 12 months) or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (three monthly pulses) followed by oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for four months; the other nine patients received identical treatment without randomization [<a href="#rid62">62</a>]. All cyclosporine-treated patients achieved resolution of nephrotic-range proteinuria within three months; proteinuria improved in only 6 of 13 patients treated with glucocorticoids. These findings were supported by those of a subsequent nationwide observational study from the same country (Finland) [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One study evaluated long-term outcomes of 62 children with IgAV (60 with nephrotic-range proteinuria) who received <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> pulses followed by oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (n = 42) or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (n = 20) as initial therapy [<a href="#rid47">47</a>]. With a mean follow-up of 10.8 years, mean eGFR at the end of follow-up was similar between the two groups (108 versus 109 mL/min/1.73 m<sup>2</sup>). Among cyclosporine-treated patients, one (5 percent) had mildly decreased kidney function (eGFR 60 to 89 mL/min/1.73 m<sup>2</sup>), two (11 percent) had persistent proteinuria, and three (17 percent) had persistent hematuria at last follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclophosphamide</strong> – <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a>, alone or with glucocorticoids, does not appear to reduce protein excretion or improve or preserve kidney function in patients with IgAV nephritis [<a href="#rid52">52,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV </strong><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> – IV immune globulin (IVIG) has been tried successfully in a small number of patients with IgA nephropathy or IgAV nephritis with heavy proteinuria and a progressive decline in glomerular filtration rate (GFR) [<a href="#rid64">64</a>]. More data are required to confirm benefit. (See  <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">"IgA nephropathy: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis</strong> – Plasmapheresis has also been used in a number of patients with severe, usually crescentic, disease and rapidly progressive kidney failure [<a href="#rid48">48,65,66</a>]. Its efficacy is uncertain (due, in part, to concurrent administration of glucocorticoids), and there are potential side effects.</p><p></p><p class="headingAnchor" id="H2686785310"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Short-term kidney outcomes in IgAV are favorable in most patients, with complete recovery reported in 94 and 89 percent of children and adults, respectively, at a mean of approximately 18 months [<a href="#rid23">23</a>]. The long-term kidney prognosis of IgAV nephritis has, in most studies, been worse in adults than in children, a finding that may be due in part to concurrent chronic kidney disease (CKD) or a longer duration between disease onset and clinical presentation [<a href="#rid23">23</a>].</p><p>Among children, the manifestations of active IgAV usually resolve spontaneously. The kidney prognosis is excellent when transient hematuria and proteinuria resolve within several months, a course that is generally associated with only focal glomerular involvement [<a href="#rid3">3,28,32</a>]. Recurrence (relapse) of IgAV is common, occurring in up to one-third of patients, and may be more likely among children with kidney involvement [<a href="#rid2">2,3,67,68</a>]. Recurrent symptoms and signs, which tend to mimic the original episode (but tend to be less severe), are normally observed within four months of resolution of the initial symptoms [<a href="#rid2">2</a>]. Recurrent disease may not predict worse long-term outcomes.</p><p>Clinical risk factors for CKD were evaluated in a meta-analysis of nine case-control studies involving 969 patients with IgAV nephritis, which found that older age at disease onset, low glomerular filtration rate (GFR), and an initial presentation with nephrotic syndrome or with nephritic-nephrotic syndrome were associated with a unfavorable kidney outcomes [<a href="#rid69">69</a>]. By contrast, an initial presentation with hematuria and mild proteinuria with or without hematuria was associated with more favorable outcomes.</p><p>In addition to these clinical predictors of prognosis, there are also pathologic predictors on kidney biopsy. In general, the extent of kidney injury parallels the clinical severity of kidney disease. The percentage of glomeruli showing crescents seems to be the most important prognostic finding. The following observations were noted in a study of 151 children referred to a major academic center and then followed for 1 to 18 years [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with crescents involving more than 50 percent of glomeruli, 37 progressed to end-stage kidney disease (ESKD), and another 18 percent had CKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients who developed ESKD, 86 percent had crescents affecting more than 50 percent of glomeruli.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Few or no crescents were seen on initial biopsy in the 70 percent of patients who recovered or had only minimal urinary abnormalities at latest examination.</p><p></p><p>In another study that evaluated histologic predictors of outcome among 159 children with IgAV nephritis, chronic glomerular (glomerulosclerosis) and tubulointerstitial lesions, but not acute glomerular (mesangial proliferation, endocapillary proliferation, crescents) and tubulointerstitial lesions, were associated with a poor kidney prognosis [<a href="#rid70">70</a>].</p><p>The Oxford Classification of IgA nephropathy, which has been shown to predict outcomes among patients with IgA nephropathy, has not been validated for adult patients with IgAV nephritis. Two small studies found that endocapillary proliferation on kidney biopsy (E1 lesion) was associated with shorter kidney survival; however, other Oxford Classification lesions were not similarly predictive [<a href="#rid71">71,72</a>]. It remains unclear whether these findings can be applied to larger populations. (See  <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">"IgA nephropathy: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H303050617"><span class="h2">Persistent and progressive disease</span><span class="headingEndMark"> — </span>A minority of affected patients have persistent kidney manifestations. This was illustrated in a population-based retrospective study of 69 Spanish children followed for a median of seven years; 12 percent had continued hematuria and proteinuria, which was strongly associated with the presence of nephrotic syndrome at diagnosis (odds ratio 23), but none had kidney function impairment [<a href="#rid73">73</a>].</p><p>Late deterioration can occur even among patients with initial complete resolution of kidney manifestations. This issue was addressed in a series of 78 children followed for 23 years; 17 had worsening kidney function, including seven with initial complete kidney function recovery [<a href="#rid28">28</a>]. Furthermore, 16 of 44 pregnancies among previously affected individuals were complicated by hypertension and/or proteinuria even in the absence of active kidney disease.</p><p>Some children progress to ESKD and require dialysis, as illustrated in the following reports [<a href="#rid26">26,28,29,32,33,36,74-76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 88 children followed for a mean of nine years, most (86 percent) had no urinary abnormalities; four had heavy proteinuria, and eight had kidney impairment, of whom three were on dialysis (3 percent) [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a different study, among 83 children followed for a mean of seven years, 7 percent became dialysis dependent, and 14 and 16 percent had a doubling of serum creatinine and persistent proteinuria, respectively [<a href="#rid74">74</a>].</p><p></p><p>Among adults, reported rates of ESKD are higher than in children, ranging from 10 to 30 percent at 15 years [<a href="#rid24">24,26,74,77-79</a>].</p><p>As with other disorders, a poor kidney prognosis is more common among those with the following disease or biopsy manifestations [<a href="#rid31">31,32,36,74,77,80</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotic syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney impairment</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Crescentic glomerulonephritis (&gt;50 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Tubulointerstitial fibrosis</p><p></p><p>Late progression may be related to persistent, active disease, as manifested by repeated episodes of macroscopic hematuria, or to irreversible nephron loss during the acute episode, leading to compensatory hyperfiltration (driven in part by intraglomerular hypertension) and hypertrophy in the remaining glomeruli. Over a period of years, these adaptive changes induce further glomerular injury that is independent of the primary disease. (See  <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H1352524182"><span class="h1">KIDNEY TRANSPLANTATION</span><span class="headingEndMark"> — </span>Kidney transplantation can be performed in patients with IgAV nephritis who progress to end-stage kidney disease (ESKD), although recurrent disease can occur [<a href="#rid81">81-85</a>]. Deposition of IgA in the graft is common, but many cases are subclinical [<a href="#rid86">86</a>]. An early study suggested that clinically relevant recurrence occurs in approximately 35 percent of patients at five years with a rate of graft loss due to recurrent disease of 11 percent [<a href="#rid81">81</a>]. Other reviews suggest a lower rate of recurrence (2.5 and 11.5 percent at 5 and 10 years in one small series) but still show a relatively high risk of graft loss due to recurrent disease [<a href="#rid84">84,87</a>]. Overall graft survival, however, appears to be the same for patients with IgAV compared with other kidney allograft recipients. (See  <a class="medical medical_review" href="/z/d/html/7344.html" rel="external">"IgA nephropathy: Recurrence after transplantation", section on 'IgA vasculitis (Henoch-Schönlein purpura)'</a>.)</p><p>The diagnosis of recurrent kidney disease is based not only upon the demonstration of mesangial IgA deposits but also clinical features of the disease, since isolated deposits can be seen without any clinical features of IgAV. It is possible that asymptomatic IgA deposits may have been present in the donor kidney prior to transplantation. Several reports have documented this phenomenon, but the IgA deposits disappeared within weeks after transplantation due, presumably, to the lack of circulating IgA-containing immune complexes in the recipient [<a href="#rid88">88,89</a>]. Thus, persistent deposits presumably reflect recurrent disease.</p><p>Recurrent glomerular disease, often in association with active extrarenal involvement, can lead to loss of the graft [<a href="#rid81">81,82,84,90</a>]. Although one study suggested that this was more likely in patients with aggressive initial disease and relatively rapid progression to ESKD [<a href="#rid81">81</a>], the association between recurrence and severity of the original disease was not confirmed in a later report [<a href="#rid84">84</a>]. It is recommended by some that transplantation be delayed for 12 to 24 months after the disappearance of purpura [<a href="#rid81">81-83</a>]. However, this approach does not prevent recurrent disease in all patients [<a href="#rid81">81</a>].</p><p>Some observations suggest that the risk of recurrent disease may be higher in recipients of living, related-donor transplants, a finding similar to that seen in IgA nephropathy [<a href="#rid83">83,84</a>]. However, one retrospective series of 339 patients reported similar rates of recurrence for those who received kidneys from deceased donors versus living, related donors (13 versus 14.3, respectively) [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H1834488027"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H3370396732"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Immunoglobulin A (IgA) vasculitis (IgAV) is characterized by the tissue deposition of IgA-containing immune complexes. The histologic findings in the kidney and presence of galactose-deficient IgA1 (Gd-IgA1) in the circulation are identical to those in IgA nephropathy, suggesting that the two disorders may have a similar pathogenesis. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>–<strong> </strong>Kidney involvement (IgAV nephritis) typically occurs within a few days to one month after the onset of systemic symptoms. The most common presentation is microscopic or macroscopic glomerular (dysmorphic) hematuria with or without red blood cell casts and mild or moderate proteinuria. Nephrotic-range proteinuria, an elevated serum creatinine, and/or hypertension are present in a minority of patients; these findings are associated with a worse kidney prognosis. IgAV nephritis is generally mild in children, while adults are more likely to develop moderate to severe disease. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of IgAV nephritis is typically based upon the clinical presentation. If further confirmation is required, a skin biopsy can be performed. A kidney biopsy is generally reserved for patients in whom the diagnosis is uncertain or who have more severe kidney involvement. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– In patients with IgAV who do not have kidney involvement at the time of presentation, we do <strong>not</strong> treat with glucocorticoids to prevent the development of IgAV nephritis. (See <a class="local">'Prevention of IgAV nephritis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Treatment of IgAV nephritis depends upon whether the patient is a child or an adult and upon the severity of the kidney disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children </strong>– In children with IgAV nephritis, our initial approach to treatment is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children who present with limited evidence of kidney involvement (ie, microscopic or macroscopic hematuria, proteinuria &lt;1 g/day, and normal serum creatinine) do not require treatment with immunosuppressive therapy for IgAV nephritis. We do not routinely initiate an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), since such patients typically fully recover without these agents. We monitor urine protein excretion once per week for one month, then every two weeks for two months to assess for disease progression. In patients who develop an increase in proteinuria to ≥1 g/day, we perform a kidney biopsy to evaluate the need for more aggressive therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For children who present with more severe kidney involvement (ie, proteinuria ≥1 g/day, elevated serum creatinine, or evidence of crescentic glomerulonephritis on kidney biopsy), we suggest immunosuppressive therapy with glucocorticoids rather than no immunosuppression or other immunosuppressive agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults </strong>– In adults with IgAV nephritis, our initial approach to treatment is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Adults who present with limited evidence of kidney involvement (ie, microscopic or macroscopic hematuria, proteinuria &lt;1 g/day, and normal serum creatinine) do not require treatment with immunosuppressive therapy for IgAV nephritis. We treat all adults with proteinuria &gt;0.5 g/day with an ACE inhibitor or ARB to reduce proteinuria, unless contraindicated. In patients who develop an increase in proteinuria to ≥1 g/day or a sustained increase in serum creatinine greater than that expected from use of an ACE inhibitor or ARB, we perform a kidney biopsy to evaluate the need for more aggressive therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For adults who present with more severe kidney involvement (ie, proteinuria ≥1 g/day, elevated serum creatinine, or evidence of crescentic glomerulonephritis on kidney biopsy), we suggest immunosuppressive therapy with glucocorticoids rather than no immunosuppression or other immunosuppressive agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, we treat all such patients with an ACE inhibitor or ARB to reduce proteinuria, unless contraindicated.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In adults who have a large number of active crescents on kidney biopsy (over 20 to 25 percent), some clinicians would treat with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF), or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in addition to the six-month course of glucocorticoids. (See <a class="local">'Adults'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child 2010; 95:877.</a></li><li><a class="nounderline abstract_t">Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999; 78:395.</a></li><li><a class="nounderline abstract_t">Trapani S, Micheli A, Grisolia F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005; 35:143.</a></li><li><a class="nounderline abstract_t">Chang WL, Yang YH, Wang LC, et al. Renal manifestations in Henoch-Schönlein purpura: a 10-year clinical study. Pediatr Nephrol 2005; 20:1269.</a></li><li><a class="nounderline abstract_t">Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population. Eur J Pediatr 1988; 147:113.</a></li><li><a class="nounderline abstract_t">Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90:916.</a></li><li><a class="nounderline abstract_t">Rieu P, Noël LH. Henoch-Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann Med Interne (Paris) 1999; 150:151.</a></li><li><a class="nounderline abstract_t">Ghrahani R, Ledika MA, Sapartini G, Setiabudiawan B. Age of onset as a risk factor of renal involvement in Henoch-Schönlein purpura. Asia Pac Allergy 2014; 4:42.</a></li><li><a class="nounderline abstract_t">Selewski DT, Ambruzs JM, Appel GB, et al. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney Int Rep 2018; 3:1373.</a></li><li><a class="nounderline abstract_t">Chan H, Tang YL, Lv XH, et al. Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis. PLoS One 2016; 11:e0167346.</a></li><li><a class="nounderline abstract_t">Wang K, Sun X, Cao Y, et al. Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch-Schönlein purpura: A retrospective study. Medicine (Baltimore) 2018; 97:e12520.</a></li><li><a class="nounderline abstract_t">Buscatti IM, Casella BB, Aikawa NE, et al. Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center. Clin Rheumatol 2018; 37:1319.</a></li><li><a class="nounderline abstract_t">Oñate I, Ortiz M, Suso A, et al. IgA vasculitis with nephritis (Henoch-Schönlein purpura) after COVID-19: A case series and review of the literature. Nefrologia (Engl Ed) 2022; 42:481.</a></li><li><a class="nounderline abstract_t">Sugita K, Kaneko S, Hisada R, et al. Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review. CEN Case Rep 2022; 11:436.</a></li><li><a class="nounderline abstract_t">Nakatani S, Mori K, Morioka F, et al. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep 2022; 11:358.</a></li><li><a class="nounderline abstract_t">Ito C, Odajima K, Niimura Y, et al. IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis. CEN Case Rep 2023; 12:84.</a></li><li><a class="nounderline abstract_t">Kauffmann RH, Herrmann WA, Meÿer CJ, et al. Circulating IgA-immune complexes in Henoch-Schönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am J Med 1980; 69:859.</a></li><li><a class="nounderline abstract_t">Kiryluk K, Moldoveanu Z, Sanders JT, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int 2011; 80:79.</a></li><li><a class="nounderline abstract_t">Meadow SR, Scott DG. Berger disease: Henoch-Schönlein syndrome without the rash. J Pediatr 1985; 106:27.</a></li><li><a class="nounderline abstract_t">O'Donoghue DJ, Darvill A, Ballardie FW. Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura. J Clin Invest 1991; 88:1522.</a></li><li><a class="nounderline abstract_t">O'Donoghue DJ, Jewkes F, Postlethwaite RJ, Ballardie FW. Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis. Clin Sci (Lond) 1992; 83:281.</a></li><li><a class="nounderline abstract_t">Heineke MH, Ballering AV, Jamin A, et al. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev 2017; 16:1246.</a></li><li><a class="nounderline abstract_t">Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, et al. Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 1997; 40:859.</a></li><li><a class="nounderline abstract_t">Kellerman PS. Henoch-Schönlein purpura in adults. Am J Kidney Dis 2006; 48:1009.</a></li><li><a class="nounderline abstract_t">Uppal SS, Hussain MA, Al-Raqum HA, et al. Henoch-Schönlein's purpura in adults versus children/adolescents: A comparative study. Clin Exp Rheumatol 2006; 24:S26.</a></li><li><a class="nounderline abstract_t">Pillebout E, Thervet E, Hill G, et al. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002; 13:1271.</a></li><li><a class="nounderline abstract_t">Audemard-Verger A, Terrier B, Dechartres A, et al. Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis Rheumatol 2017; 69:1862.</a></li><li><a class="nounderline abstract_t">Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 1992; 339:280.</a></li><li><a class="nounderline abstract_t">Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 2002; 360:666.</a></li><li><a class="nounderline abstract_t">Schärer K, Krmar R, Querfeld U, et al. Clinical outcome of Schönlein-Henoch purpura nephritis in children. Pediatr Nephrol 1999; 13:816.</a></li><li><a class="nounderline abstract_t">Austin HA 3rd, Balow JE. Henoch-Schönlein nephritis: prognostic features and the challenge of therapy. Am J Kidney Dis 1983; 2:512.</a></li><li><a class="nounderline abstract_t">Counahan R, Winterborn MH, White RH, et al. Prognosis of Henoch-Schönlein nephritis in children. Br Med J 1977; 2:11.</a></li><li><a class="nounderline abstract_t">Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 1998; 12:238.</a></li><li><a class="nounderline abstract_t">Yoshikawa N, White RH, Cameron AH. Prognostic significance of the glomerular changes in Henoch-Schoenlein nephritis. Clin Nephrol 1981; 16:223.</a></li><li><a class="nounderline abstract_t">Halling SF, Söderberg MP, Berg UB. Henoch Schönlein nephritis: clinical findings related to renal function and morphology. Pediatr Nephrol 2005; 20:46.</a></li><li class="breakAll">Habib R, Niaudet P, Levy M. Schönlein-Henoch purpura nephritis and IgA nephropathy. In: Renal Pathology with Clinical and Functional Correlations, Tisher CC, Brenner BM (Eds), Lippincott, Philadelphia 1993. p.472.</li><li><a class="nounderline abstract_t">Demir S, Kaplan O, Celebier M, et al. Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis. Semin Arthritis Rheum 2020; 50:1238.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1.</a></li><li><a class="nounderline abstract_t">Rauen T, Eitner F, Fitzner C, et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 2015; 373:2225.</a></li><li><a class="nounderline abstract_t">Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014; 86:828.</a></li><li><a class="nounderline abstract_t">Monastiri K, Selmi H, Tabarki B, et al. Primary antiphospholipid syndrome presenting as complicated Henoch-Schönlein purpura. Arch Dis Child 2002; 86:132.</a></li><li><a class="nounderline abstract_t">Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders. J Rheumatol 1992; 19:721.</a></li><li><a class="nounderline abstract_t">Dudley J, Smith G, Llewelyn-Edwards A, et al. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). Arch Dis Child 2013; 98:756.</a></li><li><a class="nounderline abstract_t">Huber AM, King J, McLaine P, et al. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. BMC Med 2004; 2:7.</a></li><li><a class="nounderline abstract_t">Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006; 149:241.</a></li><li><a class="nounderline abstract_t">Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 2019; 58:1607.</a></li><li><a class="nounderline abstract_t">Koskela M, Jahnukainen T, Endén K, et al. Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study. Pediatr Nephrol 2019; 34:1447.</a></li><li><a class="nounderline abstract_t">Balow JE. Renal vasculitis. Kidney Int 1985; 27:954.</a></li><li><a class="nounderline abstract_t">Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol 1998; 49:9.</a></li><li><a class="nounderline abstract_t">Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis. Pediatr Nephrol 1995; 9:6.</a></li><li><a class="nounderline abstract_t">Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N. Multiple combined therapy for severe Henoch-Schönlein nephritis in children. Pediatr Nephrol 1998; 12:244.</a></li><li><a class="nounderline abstract_t">Tarshish P, Bernstein J, Edelmann CM Jr. Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 2004; 19:51.</a></li><li><a class="nounderline abstract_t">Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant 2004; 19:858.</a></li><li><a class="nounderline abstract_t">Ren P, Han F, Chen L, et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. Am J Nephrol 2012; 36:271.</a></li><li><a class="nounderline abstract_t">Hackl A, Becker JU, Körner LM, et al. Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. Pediatr Nephrol 2018; 33:619.</a></li><li><a class="nounderline abstract_t">Ishiguro H, Hashimoto T, Akata M, et al. Rituximab treatment for adult purpura nephritis with nephrotic syndrome. Intern Med 2013; 52:1079.</a></li><li><a class="nounderline abstract_t">Fenoglio R, Naretto C, Basolo B, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res 2017; 65:186.</a></li><li><a class="nounderline abstract_t">Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura. J Pediatr 2009; 155:136.</a></li><li><a class="nounderline abstract_t">Maritati F, Fenoglio R, Pillebout E, et al. Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein). Arthritis Rheumatol 2018; 70:109.</a></li><li><a class="nounderline abstract_t">Shin JI, Park JM, Shin YH, et al. Cyclosporin A therapy for severe Henoch-Schönlein nephritis with nephrotic syndrome. Pediatr Nephrol 2005; 20:1093.</a></li><li><a class="nounderline abstract_t">Park JM, Won SC, Shin JI, et al. Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 2011; 26:411.</a></li><li><a class="nounderline abstract_t">Jauhola O, Ronkainen J, Autio-Harmainen H, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. Pediatr Nephrol 2011; 26:2159.</a></li><li><a class="nounderline abstract_t">Pillebout E, Alberti C, Guillevin L, et al. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int 2010; 78:495.</a></li><li><a class="nounderline abstract_t">Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med 1994; 120:476.</a></li><li><a class="nounderline abstract_t">Kauffmann RH, Houwert DA. Plasmapheresis in rapidly progressive Henoch-Schoenlein glomerulonephritis and the effect on circulating IgA immune complexes. Clin Nephrol 1981; 16:155.</a></li><li><a class="nounderline abstract_t">Hattori M, Ito K, Konomoto T, et al. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children. Am J Kidney Dis 1999; 33:427.</a></li><li><a class="nounderline abstract_t">Levy M, Broyer M, Arsan A, et al. Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp 1976; 6:183.</a></li><li><a class="nounderline abstract_t">Calvo-Río V, Hernández JL, Ortiz-Sanjuán F, et al. Relapses in patients with Henoch-Schönlein purpura: Analysis of 417 patients from a single center. Medicine (Baltimore) 2016; 95:e4217.</a></li><li><a class="nounderline abstract_t">Shi D, Chan H, Yang X, et al. Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis. PLoS One 2019; 14:e0223218.</a></li><li><a class="nounderline abstract_t">Delbet JD, Geslain G, Auger M, et al. Histological prognostic factors in children with Henoch-Schönlein purpura nephritis. Pediatr Nephrol 2020; 35:313.</a></li><li><a class="nounderline abstract_t">Inagaki K, Kaihan AB, Hachiya A, et al. Clinical impact of endocapillary proliferation according to the Oxford classification among adults with Henoch-Schönlein purpura nephritis: a multicenter retrospective cohort study. BMC Nephrol 2018; 19:208.</a></li><li><a class="nounderline abstract_t">Kim CH, Lim BJ, Bae YS, et al. Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schönlein purpura nephritis in adults. Mod Pathol 2014; 27:972.</a></li><li><a class="nounderline abstract_t">Calviño MC, Llorca J, García-Porrúa C, et al. Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore) 2001; 80:279.</a></li><li><a class="nounderline abstract_t">Coppo R, Andrulli S, Amore A, et al. Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis 2006; 47:993.</a></li><li><a class="nounderline abstract_t">Ronkainen J, Ala-Houhala M, Huttunen NP, et al. Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clin Nephrol 2003; 60:80.</a></li><li><a class="nounderline abstract_t">Shin JI, Park JM, Kim JH, et al. Factors affecting histological regression of crescentic Henoch-Schönlein nephritis in children. Pediatr Nephrol 2006; 21:54.</a></li><li><a class="nounderline abstract_t">Shrestha S, Sumingan N, Tan J, et al. Henoch Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM 2006; 99:253.</a></li><li><a class="nounderline abstract_t">Fogazzi GB, Pasquali S, Moriggi M, et al. Long-term outcome of Schönlein-Henoch nephritis in the adult. Clin Nephrol 1989; 31:60.</a></li><li><a class="nounderline abstract_t">Rauta V, Törnroth T, Grönhagen-Riska C. Henoch-Schoenlein nephritis in adults-clinical features and outcomes in Finnish patients. Clin Nephrol 2002; 58:1.</a></li><li><a class="nounderline abstract_t">Maliakkal JG, Hicks MJ, Michael M, et al. Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Meulders Q, Pirson Y, Cosyns JP, et al. Course of Henoch-Schönlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation 1994; 58:1179.</a></li><li><a class="nounderline abstract_t">Nast CC, Ward HJ, Koyle MA, Cohen AH. Recurrent Henoch-Schönlein purpura following renal transplantation. Am J Kidney Dis 1987; 9:39.</a></li><li><a class="nounderline abstract_t">Hasegawa A, Kawamura T, Ito H, et al. Fate of renal grafts with recurrent Henoch-Schönlein purpura nephritis in children. Transplant Proc 1989; 21:2130.</a></li><li><a class="nounderline abstract_t">Kanaan N, Mourad G, Thervet E, et al. Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis. Clin J Am Soc Nephrol 2011; 6:1768.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Moroni G, Glassock RJ. Recurrence of secondary glomerular disease after renal transplantation. Clin J Am Soc Nephrol 2011; 6:1214.</a></li><li><a class="nounderline abstract_t">Thervet E, Aouizerate J, Noel LH, et al. Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy. Transplantation 2011; 92:907.</a></li><li><a class="nounderline abstract_t">Samuel JP, Bell CS, Molony DA, Braun MC. Long-term outcome of renal transplantation patients with Henoch-Schonlein purpura. Clin J Am Soc Nephrol 2011; 6:2034.</a></li><li><a class="nounderline abstract_t">Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation 1982; 33:370.</a></li><li><a class="nounderline abstract_t">Cuevas X, Lloveras J, Mir M, et al. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc 1987; 19:2208.</a></li><li><a class="nounderline abstract_t">Baliah T, Kim KH, Anthone S, et al. Recurrence of Henoch-Schönlein purpura glomerulonephritis in transplanted kidneys. Transplantation 1974; 18:343.</a></li></ol></div><div id="topicVersionRevision">Topic 3107 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20852275" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575422" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16325655" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947991" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Renal manifestations in Henoch-Schönlein purpura: a 10-year clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3366130" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871983" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392264" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Henoch-Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24527410" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Age of onset as a risk factor of renal involvement in Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30450464" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902749" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30235770" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch-Schönlein purpura: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330742" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36400685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : IgA vasculitis with nephritis (Henoch-Schönlein purpura) after COVID-19: A case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35275366" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35075622" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927545" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446551" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Circulating IgA-immune complexes in Henoch-Schönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21326171" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2981307" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Berger disease: Henoch-Schönlein syndrome without the rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1939642" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327645" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29037908" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153547" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162160" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Henoch-Schönlein purpura in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16859592" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Henoch-Schönlein's purpura in adults versus children/adolescents: A comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961015" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Henoch-Schönlein Purpura in adults: outcome and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605168" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346291" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term follow-up of childhood Henoch-Schönlein nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241872" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10603128" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical outcome of Schönlein-Henoch purpura nephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6338708" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Henoch-Schönlein nephritis: prognostic features and the challenge of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/871734" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prognosis of Henoch-Schönlein nephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9630046" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7030544" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prognostic significance of the glomerular changes in Henoch-Schoenlein nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15503170" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Henoch Schönlein nephritis: clinical findings related to renal function and morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15503170" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Henoch Schönlein nephritis: clinical findings related to renal function and morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33065418" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556256" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630142" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24694989" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11827910" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Primary antiphospholipid syndrome presenting as complicated Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1613701" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845696" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15059282" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887443" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879080" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30955086" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2862306" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Renal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9491279" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7742225" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9630047" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Multiple combined therapy for severe Henoch-Schönlein nephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14634864" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15031341" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22965140" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29177628" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23676594" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rituximab treatment for adult purpura nephritis with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27449502" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19559299" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973844" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947993" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cyclosporin A therapy for severe Henoch-Schönlein nephritis with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21184240" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21626222" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20505654" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311370" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7296974" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Plasmapheresis in rapidly progressive Henoch-Schoenlein glomerulonephritis and the effect on circulating IgA immune complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070905" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/139081" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Anaphylactoid purpura nephritis in childhood: natural history and immunopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27428226" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Relapses in patients with Henoch-Schönlein purpura: Analysis of 417 patients from a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31574112" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31696358" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Histological prognostic factors in children with Henoch-Schönlein purpura nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30119643" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical impact of endocapillary proliferation according to the Oxford classification among adults with Henoch-Schönlein purpura nephritis: a multicenter retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24390221" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schönlein purpura nephritis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552081" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731294" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Predictors of outcome in Henoch-Schönlein nephritis in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940608" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16270220" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Factors affecting histological regression of crescentic Henoch-Schönlein nephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16565522" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Henoch Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646052" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-term outcome of Schönlein-Henoch nephritis in the adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12141401" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Henoch-Schoenlein nephritis in adults-clinical features and outcomes in Finnish patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32722612" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992359" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Course of Henoch-Schönlein nephritis after renal transplantation. Report on ten patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3544822" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Recurrent Henoch-Schönlein purpura following renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2652687" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fate of renal grafts with recurrent Henoch-Schönlein purpura nephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21734091" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493742" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Recurrence of secondary glomerular disease after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21869738" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700827" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long-term outcome of renal transplantation patients with Henoch-Schonlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7041362" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Fate of four cadaveric donor renal allografts with mesangial IgA deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3274493" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4609069" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Recurrence of Henoch-Schönlein purpura glomerulonephritis in transplanted kidneys.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
